Bicara Therapeutics Inc.

BCAX

Bicara Therapeutics Inc.

BCAX

Insider Sentiment (TTM):

Last Purchase:2026-02-26Last Sale:2026-05-21Shares Purchased (TTM):300,000Shares Sold (TTM):437,552

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:59,285,864Shares Outstanding:60,717,041Institutional Ownership Pct.:97.64%

Earnings Market Reaction:

Filing Date:2026-05-11Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Pharmaceutical Preparations

LLY JNJ ABBV MRK ABT PFE

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Nonrelated Party	6	6	1	-0	2	4	2
Related Party	6	6	1	-0	2	4	2
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	323	97	172	437	462	490	521
Prepaid Expense And Other Assets Current	5	7	7	8	9	13	1
Short Term Investments	-	318	118	-	-	0	-
Marketable Securities Current	216	-	-	-	-	-	-
Assets Current	545	422	297	444	471	503	522
Property Plant And Equipment Net	0	0	0	0	0	0	0
Operating Lease Right Of Use Asset	1	2	2	2	1	1	0
Long Term Investments	-	-	117	-	-	-	-
Other Assets Noncurrent	7	7	8	7	7	7	2
Assets	554	431	425	454	478	510	524
Liabilities And Stockhold…
Liabilities Current
Operating Lease Liability Current	1	1	1	1	1	1	0
Accrued Liabilities Current	-	-	-	-	-	13	-
Liabilities Current	39	29	21	17	19	18	14
Operating Lease Liability Noncurrent	0	1	1	1	0	0	0
Liabilities	40	30	22	18	19	18	15
Stockholders Equity
Other Liabilities Noncurrent	-	-	-	-	-	0	0
Preferred Stock Value	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0
Additional Paid In Capital	929	760	724	720	717	713	710
Temporary Equity Carrying Amount Attributable To P…	-	-	-	-	-	0	0
Accumulated Other Comprehensive Income Loss Net Of…	-0	0	-0	-	-	0	-
Retained Earnings Accumulated Deficit	-415	-359	-322	-285	-258	-221	-200
Stockholders Equity	514	401	403	435	459	492	510
Liabilities And Stockholders Equity	554	431	425	454	478	510	524
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0
Seed Series Redeemable Convertible Preferred Stock	-	-	-	-	-	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0
Series B Redeemable Convertible Preferred Stock	-	-	-	-	-	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0
Series C Redeemable Convertible Preferred Stock	-	-	-	-	-	0	0
Common Stock Shares Authorized	500	500	500	500	500	500	500
Temporary Equity Shares Authorized	-	-	-	-	-	-	0
Temporary Equity Shares Outstanding	-	-	-	-	-	-	0
Common Stock Shares Issued	66	57	55	55	55	54	54
Shares Outstanding	66	57	55	55	55	54	54

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-12.74%	26.53%	-	-	-	-	-	-	-	-	-	-
2025	-11.81%	-30.75%	-19.25%	15.19%	62.75%	55.21%	30.65%	17.59%	20.60%	18.96%	13.87%	22.01%
2024	-	-	-	-	-	-	-5.59%	-25.32%	-43.53%	-9.25%	7.99%	-19.10%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Liquidity Ratios
Current Ratio	13.85	14.58	14.14	25.80	24.62	27.93	36.01
Quick Ratio	13.72	14.33	13.80	25.34	24.17	27.22	35.96
Working Capital	505.58M	393.10M	276.34M	427.16M	451.63M	484.54M	507.03M
Leverage & Debt
Debt to Equity	0.08	0.07	0.05	0.04	0.04	0.04	0.03
Debt Ratio	0.07	0.07	0.05	0.04	0.04	0.04	0.03
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	-	-	-
Per Share Metrics
Diluted EPS TTM	-2.59	-2.52	-2.77	-2.42	-	-	-
Free Cash Flow Per Share TTM	-1.92	-1.96	-2.07	-2.36	-	-	-
Dividend Per Share TTM	0.00	0.00	0.00	0.00	-	-	-
Valuation Metrics
P/E TTM	-7.68	-6.67	-5.70	-3.83	-	-	-
P/B TTM	2.35	2.29	2.14	1.16	1.55	1.93	2.72
Market Cap	1.21B	920.21M	861.56M	506.67M	709.57M	947.42M	1.39B
Enterprise Value	884.20M	823.53M	689.89M	70.06M	247.50M	457.71M	864.81M
Calculated Values
Free Cash Flow TTM	-116.58M	-107.11M	-113.06M	-128.52M	-	-	-
Net Debt	-323.46M	-96.69M	-171.67M	-436.61M	-462.07M	-489.71M	-520.76M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-21Sale

Owner: Hyep, Ivan

Title: Chief Financial Officer

Shares: 9,200

Price/Share: $20.42

Value: $187,864.00

Shares Owned: 145,355

Relationship: Officer

Ownership: Direct

2026-05-18Sale

Owner: Mazumdar, Claire

Title: Chief Executive Officer

Shares: 15,000

Price/Share: $20.16

Value: $302,400.00

Shares Owned: 362,152

Relationship: Director,Officer

Ownership: Direct

2026-05-15Sale

Owner: Cohlhepp, Ryan

Title: President and COO

Shares: 12,500

Price/Share: $20.29

Value: $253,625.00

Shares Owned: 191,641

Relationship: Director,Officer

Ownership: Direct

2026-04-27Sale

Owner: Raben, David

Title: Chief Medical Officer

Shares: 5,500

Price/Share: $22.88

Value: $125,840.00

Shares Owned: 55,286

Relationship: Officer

Ownership: Direct

2026-04-21Sale

Owner: Hyep, Ivan

Title: Chief Financial Officer

Shares: 9,200

Price/Share: $23.00

Value: $211,600.00

Shares Owned: 145,355

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-21	Hyep, Ivan	Officer	Chief Financial Officer	Direct	Sale	9,200	20.42	$187,864.00	145,355	4
2026-05-18	Mazumdar, Claire	Director,Officer	Chief Executive Officer	Direct	Sale	15,000	20.16	$302,400.00	362,152	4
2026-05-15	Cohlhepp, Ryan	Director,Officer	President and COO	Direct	Sale	12,500	20.29	$253,625.00	191,641	4
2026-04-27	Raben, David	Officer	Chief Medical Officer	Direct	Sale	5,500	22.88	$125,840.00	55,286	4
2026-04-21	Hyep, Ivan	Officer	Chief Financial Officer	Direct	Sale	9,200	23.00	$211,600.00	145,355	4
2026-04-20	Mazumdar, Claire	Director,Officer	Chief Executive Officer	Direct	Sale	15,000	23.61	$354,150.00	362,152	4
2026-04-15	Cohlhepp, Ryan	Director,Officer	President and COO	Direct	Sale	12,500	23.01	$287,625.00	196,141	4
2026-03-25	Raben, David	Officer	Chief Medical Officer	Direct	Sale	5,500	18.95	$104,225.00	55,286	4
2026-03-23	Hyep, Ivan	Officer	Chief Financial Officer	Direct	Sale	9,200	18.52	$170,384.00	145,355	4
2026-03-20	Mazumdar, Claire	Director,Officer	Chief Executive Officer	Direct	Sale	1,596	18.95	$30,244.20	339,392	4
2026-03-16	Cohlhepp, Ryan	Director,Officer	President and COO	Direct	Sale	12,500	19.66	$245,750.00	200,641	4
2026-03-09	Mazumdar, Claire	Director,Officer	Chief Executive Officer	Direct	Sale	36,766	19.17	$704,804.22	339,392	4
2026-03-06	Mazumdar, Claire	Director,Officer	Chief Executive Officer	Direct	Sale	3,817	18.75	$71,568.75	339,392	4
2026-03-04	Hyep, Ivan	Officer	Chief Financial Officer	Direct	Sale	2,963	18.25	$54,074.75	145,355	4
2026-03-04	Raben, David	Officer	Chief Medical Officer	Direct	Sale	16,300	18.52	$301,876.00	55,286	4
2026-03-03	Cohlhepp, Ryan	Director,Officer	President and COO	Direct	Sale	17,392	18.16	$315,838.72	205,141	4
2026-02-26	Ra, Capital Management, L…	Director	-	Indirect	Purchase	300,000	16.00	$4,800,000.00	4,603,418	4
2026-02-25	Cohlhepp, Ryan	Director,Officer	President and COO	Direct	Sale	3,631	18.04	$65,503.24	209,641	4
2026-01-22	Cohlhepp, Ryan	Director,Officer	President and COO	Direct	Sale	3,828	18.10	$69,286.80	210,164	4
2026-01-22	Hyep, Ivan	Officer	Chief Financial Officer	Direct	Sale	1,882	18.15	$34,158.30	145,355	4
2026-01-15	Cohlhepp, Ryan	Director,Officer	President and COO	Direct	Sale	149	18.02	$2,684.98	213,992	4
2025-12-22	Hyep, Ivan	Officer	Chief Financial Officer	Direct	Sale	9,200	18.31	$168,452.00	145,355	4
2025-12-15	Cohlhepp, Ryan	Director,Officer	President and COO	Direct	Sale	12,500	18.68	$233,500.00	189,141	4
2025-11-25	Raben, David	Officer	Chief Medical Officer	Direct	Sale	5,500	18.84	$103,620.00	35,497	4
2025-11-24	Mazumdar, Claire	Director,Officer	Chief Executive Officer	Direct	Sale	41,163	18.86	$776,334.18	309,892	4
2025-11-24	Hyep, Ivan	Officer	Chief Financial Officer	Direct	Sale	17,795	18.55	$330,097.25	145,355	4
2025-11-21	Cohlhepp, Ryan	Director,Officer	President and COO	Direct	Sale	12,500	18.05	$225,625.00	193,641	4
2025-10-16	Mazumdar, Claire	Director,Officer	Chief Executive Officer	Direct	Sale	24,103	18.83	$453,859.49	309,892	4
2025-10-15	Cohlhepp, Ryan	Director,Officer	President and COO	Direct	Sale	12,500	18.16	$227,000.00	198,141	4
2025-10-15	Mazumdar, Claire	Director,Officer	Chief Executive Officer	Direct	Sale	13,289	18.84	$250,364.76	309,892	4
2025-10-09	Raben, David	Officer	Chief Medical Officer	Direct	Sale	22,000	18.45	$405,900.00	35,497	4
2025-10-09	Hyep, Ivan	Officer	Chief Financial Officer	Direct	Sale	6,415	18.23	$116,945.45	145,355	4
2025-10-08	Hyep, Ivan	Officer	Chief Financial Officer	Direct	Sale	5,627	18.21	$102,467.67	145,355	4
2025-10-07	Cohlhepp, Ryan	Director,Officer	President and COO	Direct	Sale	10,900	18.06	$196,854.00	202,641	4
2025-09-29	Meisner, Lara	Officer	Chief Legal Officer	Direct	Sale	33,807	14.75	$498,653.25	0	4
2025-09-15	Meisner, Lara	Officer	Chief Legal Officer	Direct	Sale	15,829	11.49	$181,875.21	0	4
2025-06-16	Meisner, Lara	Officer	Chief Legal Officer	Direct	Sale	15,829	10.43	$165,096.47	0	4
2025-03-14	Meisner, Lara	Officer	Chief Legal Officer	Direct	Sale	79,146	12.96	$1,025,732.16	0	4
2024-09-17	Deerfield, Private Design…	TenPercentOwner,Other	-	Indirect	Purchase	70,000	18.00	$1,260,000.00	897,587	4
2024-09-16	Ra, Capital Nexus Fund Ii…	Director,TenPercentOwner	-	Indirect	Purchase	1,833,000	18.00	$32,994,000.00	4,303,418	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

97.64%

Inst. Shares: 59,285,864

Shares Outstanding: 60,717,041

2025-12-31

94.89%

Inst. Shares: 51,882,833

Shares Outstanding: 54,676,896

2025-09-30

87.86%

Inst. Shares: 47,941,152

Shares Outstanding: 54,563,864

2025-06-30

89.72%

Inst. Shares: 48,933,094

Shares Outstanding: 54,539,230

2025-03-31

85.83%

Inst. Shares: 46,737,527

Shares Outstanding: 54,456,515

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	59,285,864	60,717,041	97.64%
2025-12-31	51,882,833	54,676,896	94.89%
2025-09-30	47,941,152	54,563,864	87.86%
2025-06-30	48,933,094	54,539,230	89.72%
2025-03-31	46,737,527	54,456,515	85.83%
2024-12-31	45,116,737	54,386,809	82.96%
2024-09-30	34,760,503	54,399,854	63.90%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Bicara Therapeutics Inc. (BCAX) — SEC Financial Statements & Analysis

Bicara Therapeutics Inc. (BCAX) is a pharmaceutical preparations company, incorporated in DE. Bicara Therapeutics Inc. trades on Nasdaq as: BCAX. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Bicara Therapeutics Inc. reported a Debt-to-Equity ratio of 0.08x, a Price-to-Book (P/B) ratio of 2.35 (TTM), at a market cap of $1.21B. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.08x
P/B TTM: 2.35
Market Cap: $1.21B

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Bicara Therapeutics Inc. in?

Bicara Therapeutics Inc. (BCAX) operates in the Pharmaceutical Preparations industry.

What is BCAX's market cap?

Bicara Therapeutics Inc. (BCAX) has a market capitalization of $1.21B as of 2026-03-31.

What exchange does BCAX trade on?

Bicara Therapeutics Inc. (BCAX) trades on the Nasdaq.

Where is Bicara Therapeutics Inc. incorporated?

Bicara Therapeutics Inc. is incorporated in DE.

Bicara Therapeutics Inc. (BCAX) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.